TRAF3

2 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

2 independent labs in 1 country

Humans1
Animals1

Effects

Sarcopenia

downin mice1

1 study

TRAF3 prevents sarcopenia in mice.
“Genetic deletion of TRAF3 in myocytes or satellite cells induced early-onset sarcopenia and impaired regeneration, independent of non-canonical NF-κB signaling.”
Animalsshown by genetic deletion in myocytes or satellite cellsskeletal muscle
Inflammaging-induced TRAF3 degradation impairs AMP biosynthesis to drive sarcopenia
Research square20 Mar 2026Preprint

Upstream

TGFB1

downin mice1

1 study

TGFB1 inhibits TRAF3 in mice.
“Notably, neutrophil-derived transforming growth factor β1 (TGFβ1) caused IAP-mediated ubiquitination and degradation of TRAF3 in aged mice-a process reversible by the IAP inhibitor SM-164.”
Animalsin aged mice
Inflammaging-induced TRAF3 degradation impairs AMP biosynthesis to drive sarcopenia
Research square20 Mar 2026Preprint